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Abstract. Leishmania parasites cause a broad range of disease, with cutaneous afflictions being, by far, the most
prevalent. Variations in disease severity and symptomatic spectrum are mostly associated to parasite species. One risk
factor for the severity and emergence of leishmaniasis is immunosuppression, usually arising by coinfection of the
patient with human immunodeficiency virus (HIV). Interestingly, several species of Leishmania have been shown to
bear an endogenous cytoplasmic dsRNA virus (LRV) of the Totiviridae family, and recently we correlated the presence
of LRV1 within Leishmania parasites to an exacerbation murine leishmaniasis and with an elevated frequency of drug
treatment failures in humans. This raises the possibility of further exacerbation of leishmaniasis in the presence of both
viruses, and here we report a case of cutaneous leishmaniasis caused by Leishmania braziliensis bearing LRV1 with
aggressive pathogenesis in an HIV patient. LRV1 was isolated and partially sequenced from skin and nasal lesions.
Genetic identity of both sequences reinforced the assumption that nasal parasites originate from primary skin lesions.
Surprisingly, combined antiretroviral therapy did not impact the devolution of Leishmania infection. The Leishmania
infection was successfully treated through administration of liposomal amphotericin B.
INTRODUCTION
Leishmania parasites infect over 2 million people annually
and cause a broad range of disease, with cutaneous afflic-
tions being, by far, the most prevalent.1 Variations in disease
severity and symptomatic spectrum are mostly associated with
parasite species. This is reflected by the geographical distribu-
tion of severely disseminated (DL) and mucosal leishmani-
ases (ML), which occur predominantly in Central and South
America and Ethiopia. Leishmania braziliensis, Leishmania
panamensis, Leishmania guyanensis, and Leishmania aethio-
pica are the main causative species of these aggressive
forms of leishmaniasis, which progress from a primary cuta-
neous lesion in 5–10% of infected patients.2,3
Leishmania braziliensis, L. guyanensis, and L. aethiopica
species are known to be variously infected by Leishmania
RNA virus (LRV), a cytoplasmic double-stranded RNA
(dsRNA) virus of the Totiviridae family.2,4,5 LRV presence is
predominant in the Amazonian basin.6 Previously, we showed
that this virus (LRV1) within the L. guyanensis parasites
exacerbates disease outcome in a murine model by inducing
a hyperinflammatory response with increased interferon β,7
and inflammatory markers commonly found in the lesions of
ML patients.8,9 Recently, we and collaborators showed that
the presence of LRV1 in L. guyanensis and L. braziliensis is
a risk factor for relapse in drug-treated patients.10,11
Leishmaniasis is a rising opportunistic complication in human
immunodeficiency virus (HIV)–positive individuals.12 Although
it is well known that the parasite can take advantage of the
concomitant acquired immunodeficiency syndrome (AIDS)–
related immunosuppression, potentially this could be further
exacerbated by the presence of LRV1 within the infecting
parasite. In this case report, we recount the clinical presen-
tation, diagnosis, and successful treatment of this severe
cutaneous leishmaniasis in an HIV-positive patient caused by
L. braziliensis and its cytoplasmic virus.
CASE REPORT
The patient, a 60-year-old female, presented at the clinic
with several skin ulcerations on the limbs and trunk. The
patient had been living in Paraguay for the three previous
years and her lesions first developed 9 months earlier during
a 1-month stay in Bolivia, where she was treated empirically
for bacterial ecthyma. A concomitant HIV test was found pos-
itive after which she decided to travel back to Switzerland
for further medical management. The initial physical exami-
nation revealed several large, ovoid skin ulcerations, ranging
from 5 to 15 cm in diameter, with raised erythematic borders
and a clear exudate (Figure 1A and B). The patient was
apyretic and had no additional complaints.
Combined antiretroviral therapy (cART) with tenofovir,
emtricitabine, and efavirenz was initiated based on a high
viremia of 1,764 copies/mL (CD4-cell count of 803 cells/μL)
and on the presence of a coinfecting Leishmania parasite.
Treatment decreased viremia to 482 copies/mL after 2 months.
The patient’s skin lesions, however, continued to slowly
progress, at which point she was referred to the dermatology
department for further evaluation.
In addition to the skin lesions, the patient complained
of a recently acquired unilateral rhinitis and nasal conges-
tion. A nasal endoscopy revealed unilateral focal granulo-
matous hyperplasia of the head of the middle turbinate
(Figure 1C). Magnetic resonance imaging showed no cartilag-
inous destruction or paranasal involvement. ML was sus-
pected. Touch preparations from skin exudates disclosed no
Leishmania amastigotes, and biopsies from lesion borders
and nasal granulomatous tissue revealed chronic nonspecific
inflammation, with no Leishmania, fungal, or mycobacterial
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organisms (by Giemsa, periodic acid–Schiff, and Ziehl–Neelsen
stains, respectively).
On admission, a blood sample and two intralesional biop-
sies were isolated from the patient: one from a cutaneous
lesion and the other from a metastatic lesion in the nasal
mucosa. Two standard leishmanial diagnostic procedures
(in vitro cultivation and polymerase chain reaction [PCR])
were undertaken on each of the three isolates. Leishmania
parasites could be expanded from both cutaneous and nasal
mucosa specimens, albeit absent in blood samples. PCR
amplified a standard leishmanial diagnostic marker (internal
transcribed spacer 1 of Leishmania small subunit ribosomal
RNA).13 Direct sequencing of the amplified products was
obtained and comparative sequence analysis of the diag-
nostic PCR products was done by applying the nucleotide
BLAST® algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
(GeneBank™ sequence database; accession no. JN936955).
The alignment of the PCR products categorized both para-
site isolates as L. braziliensis. Isolates were thereafter assigned
World Health Organization format identifiers MHOM/BO/
2011/2169 (Lb2169, skin lesion) and MHOM/BO/2011/2192
(Lb2192, nasal lesion).
Considering that our patient had a severely disseminated
form of cutaneous leishmaniasis and an inflamed nasal mucosa,
we determined that the L. braziliensis parasites from these
lesions were infected by LRV1.14 We completed our study by
obtaining pure LRV1 dsRNA after reverse transcription into
complementary DNA (cDNA), performing PCR amplifica-
tion using 10 primers (information available at: http://people
.unil.ch/nicolasfasel/supptab1_lbhiv/) and sequencing 4,969 bp
of this dsRNA (GenBank accession no. KC862308). Its
structure paralleled the open reading frames of previously
sequenced LRV1 isolated from L. guyanensis parasites (data
not shown). An LRV1-specific PCR of parasite cDNA prep-
arations from isolated viral dsRNA of both isolates was
sequenced, confirming LRV1 presence in both isolates. The
genetic identity of LRV1 between both isolates supports the
assumption that mucosal parasites had migrated from pri-
mary skin lesions.
Although the standard first-line treatment of ML relies on
pentavalent antimony (sodium stibogluconate or meglumine
antimoniate),15,16 we opted for a second-line therapy with
liposomal amphotericin B,17 whose efficacy and tolerance
profiles are favorable in DL as well as in HIV-coinfected
patients and for treatment of antimony-resistant strains.18
Our choice was motivated by the evolution and severity of
the disease, where numerous, large diameter (up to 15 cm)
skin lesions had evolved and persisted for over 10 months,
together with the potentially disfiguring involvement of the
nasal mucosa.
The patient received intravenous liposomal amphotericin B
for five successive days at 3 mg/kg (150 mg per infusion) with
two additional infusions at days 14 and 21 (cumulative dose:
21 mg/kg, i.e., 1,050 mg). The cutaneous lesions of the limbs
and trunk began to heal 2 weeks after treatment initiation and
were completely re-epithelialized after 1 month (Figure 1D
and E). The nasal mucosa required additional liposomal ampho-
tericin infusions (cumulative dose: 27 mg/kg, i.e., 1,350 mg) to
achieve complete healing with no residual deformation of the
nasal structure (Figure 1F). Six months posttreatment, the
patient had no infectious relapse and displayed only mild
discoloration of the healed wounds.
DISCUSSION
This study was the first account of a patient coinfected
with HIV and a strain of L. braziliensis carrying the cyto-
plasmic dsRNA virus, LRV1. The patient presented with a
particularly exacerbated form of cutaneous leishmaniasis,
with individual metastatic skin lesions measuring up to 15 cm
in diameter as well as a further parasitic infestation in the
nasal mucosa. Although DL may present with ulcers and/
FIGURE 1. Cutaneous and mucosal metastatic leishmaniasis caused by Leishmania RNA virus–laden Leishmania braziliensis in a human
immunodeficiency virus–coinfected patient. Pre-therapeutic examination (A–C) finds large well-demarcated skin ulcerations of the axillary
regions and posterior trunk (A and B) while a nasal endoscopy (C) reveals granulomatous inflammation of the nasal mucosa on the head of the
middle turbinate. One month after AmBisome treatment, skin lesions healed completely with mild discoloration and scarring (D and E). Nasal
lesions resolved 3 months later after an additional round of AmBisome therapy (F).
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or mucosal involvement, even in HIV-negative patients,19–21
this patient’s symptomology was distinct from that of
L. braziliensis DL21 and from HIV/L. braziliensis coinfec-
tions because of the number of large ulcerated disseminated
lesions.22 Although exacerbations of leishmaniasis are com-
mon in HIV coinfection due to a collapse of the CD4 T-cell
compartment, the patient described here had a low CD4-cell
count at the start of cART. Further, cART had no effect on
disease progression, contrary to visceral leishmaniasis/HIV
coinfection, where restoration of the CD4-cell count usually
results in a significant amelioration of disease. Quite oppo-
sitely, the patient condition did not improve clinically with
progressing cutaneous lesions.
The presence of Leishmania along with two viruses (one
internal, one external) could underlie this severe form of
disease, and may potentially explain some of the unusual
manifestations of American tegumentary leishmaniasis caused
by L. braziliensis or L. guyanensis reported in HIV-positive
patients,23,24 which are especially frequent in regions of South
America where LRV1 is known to be most prevalent, such
as French Guyana and the Brazilian Amazon.25,26 Indeed,
HIV and LRV dsRNA may synergize to worsen leishmani-
asis, where HIV coinfection not only increases the incidence
of Leishmania infection, but also the patient’s risk of devel-
oping metastatic or chronic complications of leishmaniasis.
The retrospective nature of this report and the lack of epi-
demiological data did not allow us to definitively ascertain
the joint detrimental roles of LRV1 and HIV in human leish-
manial disease progression. However, we can hypothesize
that the clinical presentation reported here of LRV1-carrying
Leishmania infection is in line with what is observed in relapses
in L. braziliensis- and L. guyanensis-infected patients and in
experimental animal models and could explain some of the
unusual manifestations of American tegumentary leishman-
iasis reported in HIV-positive patients,23,24,27 as well as the
commonly observed treatment failures and relapses.10–12,26
Using PCR conditions and primers described in this study, a
large-scale screen for LRV1 as a risk factor in leishmaniasis
patients will be instrumental to unlocking the potential of
exploiting this nested viral infection for use as a diagnostic
and prognostic marker.
ReceivedNovember 9, 2015. Accepted for publicationDecember 17, 2015.
Published online February 1, 2016.
Acknowledgments: We thank F. Matthew Kuhlmann for advice and
critical reading of the manuscript.
Financial support: This work was funded by the grants FNRS no.
3100A0-116665/1, IZ70Z0-131421 and from aIAR to Nicolas Fasel
and NIH grants AI29646 and AI099364 to Stephen M. Beverley.
Authors’ addresses: Laurent Parmentier, Dermatology, Hôpitaux du
Valais, Sierre, Switzerland, E-mail: laurent.parmentier@hospitalvs.ch.
Alexia Cusini, Infectious Diseases Unit, Cantonal Hospital, Chur,
Switzerland, E-mail: alexia.cusini@ksgr.ch. Norbert Müller, Institute
of Parasitology, Vetsuisse Faculty Bern, University of Bern, Bern,
Switzerland, E-mail: norbert.mueller@vetsuisse.unibe.ch. Haroun
Zangger, Mary-Anne Hartley, Chantal Desponds, Patrik Castiglioni,
Catherine Ronet, and Nicolas Fasel, Department of Biochemistry, Uni-
versity of Lausanne, Lausanne, Switzerland, E-mails: haroun.zangger@
vd.educanet2.ch, hartley.annie@gmail.com, chantal.desponds@unil.ch,
patrik.castiglioni@unil.ch, catherine.ronet@unil.ch, and nicolas.fasel@
unil.ch. Patrick Dubach, Ear Neck Throat Surgery, Bürgerspital,
Solothurn, Switzerland, E-mail: patrick.dubach@spital.so.ch. Stephen M.
Beverley, Department of Molecular Microbiology, Washington University
School of Medicine, St. Louis, MO, E-mail: beverley@wusm.wustl.edu.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
REFERENCES
1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J,
Jannin J, den Boer M; WHO Leishmaniasis Control Team,
2012. Leishmaniasis worldwide and global estimates of its inci-
dence. PLoS One 7: e35671.
2. Zangger H, Hailu A, Desponds C, Lye LF, Akopyants NS,
Dobson DE, Ronet C, Ghalib H, Beverley SM, Fasel N,
2014. Leishmania aethiopica field isolates bearing an endo-
symbiontic dsRNA virus induce pro-inflammatory cytokine
response. PLoS Negl Trop Dis 8: e2836.
3. Hartley MA, Drexler S, Ronet C, Beverley SM, Fasel N, 2014.
The immunological, environmental, and phylogenetic perpetra-
tors of metastatic leishmaniasis. Trends Parasitol 30: 412–422.
4. Tarr PI, Aline RF Jr, Smiley BL, Scholler J, Keithly J, Stuart K,
1988. LR1: a candidate RNA virus of Leishmania. Proc Natl
Acad Sci USA 85: 9572–9575.
5. Widmer G, Comeau AM, Furlong DB, Wirth DF, Patterson JL,
1989. Characterization of a RNA virus from the parasite
Leishmania. Proc Natl Acad Sci USA 86: 5979–5982.
6. Salinas G, Zamora M, Stuart K, Saravia N, 1996. Leishmania
RNA viruses in Leishmania of the Viannia subgenus. Am J
Trop Med Hyg 54: 425–429.
7. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S,
Schutz F, Zangger H, Revaz-Breton M, Lye LF, Hickerson
SM, Beverley SM, Acha-Orbea H, Launois P, Fasel N, Masina
S, 2011. Leishmania RNA virus controls the severity of muco-
cutaneous leishmaniasis. Science 331: 775–778.
8. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa
JL, Reed S, Rocha H, 1985. Cell mediated immunity in
American cutaneous and mucosal leishmaniasis. J Immunol
135: 4144–4148.
9. Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD,
Corbett CE, 2009. Immunopathogenic competences of Leish-
mania (V.) braziliensis and L. (L.) amazonensis in American
cutaneous leishmaniasis. Parasite Immunol 31: 423–431.
10. Bourreau E, Ginouves M, Prevot G, Hartley MA, Gangneux JP,
Robert-Gangneux F, Dufour J, Sainte-Marie D, Bertolotti A,
Pratlong F, Martin R, Schutz F, Couppie P, Fasel N, Ronet C,
2015. Presence of Leishmania RNA virus 1 in Leishmania
guyanensis increases the risk of first-line treatment failure and
symptomatic relapse. J Infect Dis 213: 105–111.
11. Adaui V, Lye LF, Akopyants NS, Zimic M, Llanos-Cuentas A,
Garcia L, Maes I, De Doncker S, Dobson DE, Arevalo J,
Dujardin JC, Beverley SM, 2015. Association of the endo-
biont double-stranded RNA virus LRV1 with treatment fail-
ure for human leishmaniasis caused by Leishmania braziliensis
in Peru and Bolivia. J Infect Dis 213: 112–121.
12. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet
JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J, 2008.
The relationship between leishmaniasis and AIDS: the second
10 years. Clin Microbiol Rev 21: 334–359.
13. el Tai NO, Osman OF, el Fari M, Presber W, Schonian G, 2000.
Genetic heterogeneity of ribosomal internal transcribed
spacer in clinical samples of Leishmania donovani spotted on
filter paper as revealed by single-strand conformation poly-
morphisms and sequencing. Trans R Soc Trop Med Hyg 94:
575–579.
14. Zangger H, Ronet C, Desponds C, Kuhlmann FM, Robinson J,
Hartley MA, Prevel F, Castiglioni P, Pratlong F, Bastien P,
Muller N, Parmentier L, Saravia NG, Beverley SM, Fasel
N, 2013. Detection of Leishmania RNA virus in Leishmania
parasites. PLoS Negl Trop Dis 7: e2006.
15. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B,
Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis
7: 581–596.
16. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC, 2008.
Mucosal leishmaniasis. Current scenario and prospects for
treatment. Acta Trop 105: 1–9.
842 PARMENTIER, CUSINI AND OTHERS
17. Machado PR, Rosa ME, Guimaraes LH, Prates FV, Queiroz A,
Schriefer A, Carvalho EM, 2015. Treatment of disseminated
leishmaniasis with liposomal amphotericin B. Clin Infect Dis
61: 945–949.
18. Amato VS, Nicodemo AC, Amato JG, Boulos M, Neto VA,
2000. Mucocutaneous leishmaniasis associated with HIV
infection treated successfully with liposomal amphotericin B
(AmBisome). J Antimicrob Chemother 46: 341–342.
19. Costa JM, Marsden PD, Llanos-Cuentas EA, Netto EM,
Carvalho EM, Barral A, Rosa AC, Cuba CC, Magalhaes AV,
Barreto AC, 1986. Disseminated cutaneous leishmaniasis in a
field clinic in Bahia, Brazil: a report of eight cases. J Trop
Med Hyg 89: 319–323.
20. Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P,
1994. Clinical and immunopathological aspects of dissemi-
nated cutaneous leishmaniasis. Acta Trop 56: 315–325.
21. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A,
Almeida RP, Mobashery N, Johnson WD Jr, Carvalho EM,
2002. Disseminated leishmaniasis: a new and emerging form
of leishmaniasis observed in northeastern Brazil. J Infect Dis
186: 1829–1834.
22. Machado ES, Braga Mda P, Da Cruz AM, Coutinho SG, Vieira
AR, Rutowitsch MS, Cuzzi-Maya T, Grimaldi G Jr, Menezes
JA, 1992. Disseminated American muco-cutaneous leishmania-
sis caused by Leishmania braziliensis braziliensis in a patient
with AIDS: a case report. Mem Inst Oswaldo Cruz 87: 487–492.
23. Lindoso JA, Barbosa RN, Posada-Vergara MP, Duarte MI,
Oyafuso LK, Amato VS, Goto H, 2009. Unusual manifesta-
tions of tegumentary leishmaniasis in AIDS patients from the
New World. Br J Dermatol 160: 311–318.
24. Goto H, Lindoso JA, 2010. Current diagnosis and treatment of
cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti
Infect Ther 8: 419–433.
25. Couppie P, Clyti E, Sobesky M, Bissuel F, Del Giudice P,
Sainte-Marie D, Dedet JP, Carme B, Pradinaud R, 2004. Com-
parative study of cutaneous leishmaniasis in human immuno-
deficiency virus (HIV)-infected patients and non-HIV-infected
patients in French Guiana. Br J Dermatol 151: 1165–1171.
26. Guerra JA, Coelho LI, Pereira FR, Siqueira AM, Ribeiro RL,
Almeida TM, Lacerda MV, Barbosa M, Talhari S, 2011.
American tegumentary leishmaniasis and HIV-AIDS associa-
tion in a tertiary care center in the Brazilian Amazon. Am J
Trop Med Hyg 85: 524–527.
27. de Souza e Souza I, Naiff RD, Guimaraes TC, Naiff MF, Cupolillo
E, Rodrigues WA, Schettini AP, 1998. American cutaneous
leishmaniasis due to Leishmania (Viannia) guyanensis as an ini-
tial clinical presentation of human immunodeficiency virus
infection. J Eur Acad Dermatol Venereol 10: 214–217.
843LEISHMANIA RNAVIRUS AND HIV
